Investigational drug · Phase 3
VDPHL01
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Androgenetic Alopecia, AGA, Male Pattern Baldness.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
4
Any phase or sponsor naming "VDPHL01"
First trial start
2024
Jul 8, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VDPHL01", any sponsor or status.
Conditions studied
As listed on its trial records.
- Androgenetic Alopecia
- AGA
- Male Pattern Baldness
- Androgenetic Alopecia (AGA)
- Female Androgenetic Alopecia
- Hair Loss
Approved drugs for the same conditions: Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "VDPHL01" as an intervention, largest first.
- Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)Pivotal-lookingActive, not recruiting
Veradermics, Inc.Industry
NCT07146022 · 552 participants (planned) · Start Jul 25, 2025 · Primary completion Jun 2027
Drug: VDPHL01 QD; Placebo and 2 more · For: Androgenetic Alopecia (AGA); Androgenetic Alopecia; AGA and 2 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Fort Smith, Arkansas · 71 sites in all
- Efficacy and Safety of VDPHL01 in Males With AGAPivotal-lookingActive, not recruiting
Veradermics, Inc.Industry
NCT06724614 · 480 participants (planned) · Start Nov 6, 2024 · Primary completion Feb 2026
Drug: VDPHL01; Placebo · For: Androgenetic Alopecia; AGA; Male Pattern Baldness
Sites: Birmingham, Alabama; Phoenix, Arizona; Fort Smith, Arkansas · 44 sites in all
- Safety and Efficacy of VDPHL01 in Males With AGAPivotal-lookingActive, not recruiting
Veradermics, Inc.Industry
NCT06972264 · 480 participants (planned) · Start Mar 11, 2025 · Primary completion Dec 2026
Drug: VDPHL01; Placebo · For: Androgenetic Alopecia; AGA; Male Pattern Baldness
Sites: Birmingham, Alabama; Phoenix, Arizona; Encino, California · 44 sites in all
- Safety and Efficacy of VDPHL01 in Males and Females With AGAActive, not recruiting
Veradermics, Inc.Industry
NCT06527365 · 70 participants (planned) · Start Jul 8, 2024 · Primary completion Aug 2026
Drug: VDPHL01 · For: Androgenetic Alopecia; AGA; Male Pattern Baldness
Sites: San Diego, California; New Albany, Indiana; Hackensack, New Jersey · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Androgenetic Alopecia
- PP405 0.05%PP405Phase 33 trials
Pelage Pharmaceuticals, Inc. · Androgenetic Alopecia
- DA-001Phase 31 trial
Applied Biology, Inc. · Telogen Effluvium, Female Pattern Hair Loss, Female Pattern Hair Loss, Androgenic Alopecia
- SecretomeConditioned, Umbilical Cord Mesenchymal Stem Cells derived ConditionedPhase 24 trials
PT. Prodia Stem Cell Indonesia · Acute Respiratory Distress Syndrome, Androgenetic Alopecia, Ischemic Stroke
- AD-3031Phase 21 trial
Moogene Medi Co., Ltd · Androgenetic Alopecia
- AD-303APhase 21 trial
Moogene Medi Co., Ltd · Androgenetic Alopecia
- EPI-001Phase 21 trial
Epibiotech · Androgenetic Alopecia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.